NASDAQ · LVTX
Healthcare · Biotechnology
$1.74
Down-$0.07 (-3.87%)
Updated Aug 23, 2026, 1:11 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
LVTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning LVTX.
LVTX research
Company profile and research snapshot.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2025 | HC Wainwright & Co. | Neutral | — |
| Aug 5, 2025 | Jefferies | Hold | — |
| May 15, 2025 | JMP Securities | Market Perform | — |
| Mar 31, 2025 | HC Wainwright & Co. | Neutral | — |
| Feb 27, 2025 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
defenseworld.net · Dec 8, 2025
LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has received an average rating of "Reduce" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a hold rating on the company. The average 1 year price
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LVTX.
No results
No recent SID articles mention LVTX.
